Syncona (SYNC) says that its portfolio company, Achilles Therapeutics Plc, has announced that its board has recommended a members’ solvent voluntary liquidation and a return of capital to shareholders. SYNC’s announcement says that, based on the information currently available to Achilles and, assuming that Achillies’ shareholders approve the liquidation proposals and associated resolutions, it is currently expected that Achilles’ ordinary shareholders will receive approximately £1.20 to £1.32 per share or US$1.50 to US$1.66 per share through the voluntary liquidation.
SYNC currently holds 11,086,909 American Depositary Shares (ADSs), representing 11,086,909 ordinary shares in Achilles and, as of 30 September 2024,…
